Cargando…
The Use of Apatinib in Treating Nonsmall-Cell Lung Cancer: Case Report and Review of Literature
Apatinib is a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2, which has been proved to be effective and safe in treating heavily pretreated patients with gastric cancer. The aim of the study was to explore the use of apatinib in treatment of nonsmall cell lun...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902403/ https://www.ncbi.nlm.nih.gov/pubmed/27196461 http://dx.doi.org/10.1097/MD.0000000000003598 |
_version_ | 1782436984329863168 |
---|---|
author | Ding, Lin Li, Qing-Jian You, Kai-Yun Jiang, Zhi-Min Yao, He-Rui |
author_facet | Ding, Lin Li, Qing-Jian You, Kai-Yun Jiang, Zhi-Min Yao, He-Rui |
author_sort | Ding, Lin |
collection | PubMed |
description | Apatinib is a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2, which has been proved to be effective and safe in treating heavily pretreated patients with gastric cancer. The aim of the study was to explore the use of apatinib in treatment of nonsmall cell lung cancer and its side effects. We report 2 patients presented with advanced nonsmall-cell lung cancer, who received apatinib after failure in the first- or third-line chemotherapy. They are treated with apatinib in daily dose of 850 mg, 28 days per cycle. Favorable oncologic outcomes were achieved in the 2 cases after the treatment of apatinib. Patient I's progression-free-survival has increased to 4.6 months after palliative therapy of apatinib, whereas Patient II nearly 6 months. The common side effects of apatinib were hypertension and hand-foot syndrome; however, the toxicity of apatinib was controllable and tolerable. Apatinib may be an option for advanced nonsmall cell lung cancer after failure of chemotherapy or other targeted therapy. But that still warrants further investigation in the prospective study. |
format | Online Article Text |
id | pubmed-4902403 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-49024032016-06-23 The Use of Apatinib in Treating Nonsmall-Cell Lung Cancer: Case Report and Review of Literature Ding, Lin Li, Qing-Jian You, Kai-Yun Jiang, Zhi-Min Yao, He-Rui Medicine (Baltimore) 5700 Apatinib is a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor-2, which has been proved to be effective and safe in treating heavily pretreated patients with gastric cancer. The aim of the study was to explore the use of apatinib in treatment of nonsmall cell lung cancer and its side effects. We report 2 patients presented with advanced nonsmall-cell lung cancer, who received apatinib after failure in the first- or third-line chemotherapy. They are treated with apatinib in daily dose of 850 mg, 28 days per cycle. Favorable oncologic outcomes were achieved in the 2 cases after the treatment of apatinib. Patient I's progression-free-survival has increased to 4.6 months after palliative therapy of apatinib, whereas Patient II nearly 6 months. The common side effects of apatinib were hypertension and hand-foot syndrome; however, the toxicity of apatinib was controllable and tolerable. Apatinib may be an option for advanced nonsmall cell lung cancer after failure of chemotherapy or other targeted therapy. But that still warrants further investigation in the prospective study. Wolters Kluwer Health 2016-05-20 /pmc/articles/PMC4902403/ /pubmed/27196461 http://dx.doi.org/10.1097/MD.0000000000003598 Text en Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. http://creativecommons.org/licenses/by/4.0 This is an open access article distributed under the Creative Commons Attribution License 4.0, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0 |
spellingShingle | 5700 Ding, Lin Li, Qing-Jian You, Kai-Yun Jiang, Zhi-Min Yao, He-Rui The Use of Apatinib in Treating Nonsmall-Cell Lung Cancer: Case Report and Review of Literature |
title | The Use of Apatinib in Treating Nonsmall-Cell Lung Cancer: Case Report and Review of Literature |
title_full | The Use of Apatinib in Treating Nonsmall-Cell Lung Cancer: Case Report and Review of Literature |
title_fullStr | The Use of Apatinib in Treating Nonsmall-Cell Lung Cancer: Case Report and Review of Literature |
title_full_unstemmed | The Use of Apatinib in Treating Nonsmall-Cell Lung Cancer: Case Report and Review of Literature |
title_short | The Use of Apatinib in Treating Nonsmall-Cell Lung Cancer: Case Report and Review of Literature |
title_sort | use of apatinib in treating nonsmall-cell lung cancer: case report and review of literature |
topic | 5700 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4902403/ https://www.ncbi.nlm.nih.gov/pubmed/27196461 http://dx.doi.org/10.1097/MD.0000000000003598 |
work_keys_str_mv | AT dinglin theuseofapatinibintreatingnonsmallcelllungcancercasereportandreviewofliterature AT liqingjian theuseofapatinibintreatingnonsmallcelllungcancercasereportandreviewofliterature AT youkaiyun theuseofapatinibintreatingnonsmallcelllungcancercasereportandreviewofliterature AT jiangzhimin theuseofapatinibintreatingnonsmallcelllungcancercasereportandreviewofliterature AT yaoherui theuseofapatinibintreatingnonsmallcelllungcancercasereportandreviewofliterature AT dinglin useofapatinibintreatingnonsmallcelllungcancercasereportandreviewofliterature AT liqingjian useofapatinibintreatingnonsmallcelllungcancercasereportandreviewofliterature AT youkaiyun useofapatinibintreatingnonsmallcelllungcancercasereportandreviewofliterature AT jiangzhimin useofapatinibintreatingnonsmallcelllungcancercasereportandreviewofliterature AT yaoherui useofapatinibintreatingnonsmallcelllungcancercasereportandreviewofliterature |